Oral Norovirus Vaccine Study on Healthy Subjects

Eligibility Details: Inclusion Criteria: - Male or female between the ages of 18 to 49 years, inclusive - General good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratories - Demonstrate comprehension of the protocol procedures and willingness to adhere to all visits and assessments - Body mass index between 17 and 35 at screening - Female subjects must have a negative pregnancy test at screening and before each vaccination and fulfill protocol specified criteria for adequate birth control. Exclusion Criteria: - Presence of a significant medical condition which in the opinion of the investigator precludes participation in the study - History of cancer or cancer treatment within past 3 years - Presence of immunosuppression or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus or angioedema - Donation or use of blood/blood products within 4 weeks prior to vaccination - Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic. - Any condition that resulted in the absence or removal of the spleen - Positive HIV, HBsAg or HCV tests at the screening visit - Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days of vaccination - Use of medications known to affect the immune function within 14 days of vaccination - Use of NSAIDs, sulfonylureas, and angiotensin II blockers within 7 days of vaccination - Evidence of recent or of current nonbacterial gastroenteritis suggestive of NV infection to any gastroenteritis within 2 weeks of vaccination - History of drug, alcohol or chemical abuse within 1 year of screening or positive urine drug test at screening - Consistent/habitual smoking within 2 months as per medical history - History of hypersensitivity or allergic reaction to any component of the investigational vaccine or placebo - Use of any investigational vaccine, drug or device within 8 weeks preceding vaccination, or planned use of the above stated for the duration of the study